ABSTRACT: Interleukin(IL)-18 is an interferon (IFN)-c-inducing cytokine suggested to be important in regulating inflammatory responses. This study investigated the pulmonary expression of IL-18 under conditions characterized by T-helper (Th)1 (lipopolysaccharide (LPS) treatment/sarcoidosis) and Th2 (ovalbumin (OVA) challenge/asthma) cytokine production.
Interleukin (IL)-18 is an 18.3 kDa protein first identified in murine Kupffer cells following treatment with Propionibacterium acnes and lipopolysaccharide (LPS) challenge [1] . Initially, IL-18 was termed interferon (IFN)-c-inducing factor (IGIF) by OKAMURA et al. [1] due to its ability to induce IFN-c production in established T-helper (Th)1 clones. In this system, IL-12 and IL-18 were shown to act on the T-cells in an independent but synergistic fashion [1] . While there is controversy regarding whether IL-18 can act independently of IL-12 [2±5], BARBULESCU et al. [6] have demonstrated that in peripheral blood CD4 T-cells, IL-18 acts directly on the IFN-c promoter to induce high cytokine expression.
In addition to T-cells, IL-18 can induce IFN-c production in natural killer (NK) cells, enhancing their cytotoxic activity [7] , B cells, initiating immunoglobulin (Ig)G2a production and suppression of IgE [2] and bone marrow derived macrophages, providing autocrine activation of these cells [3] . Despite the fact that IL-18 is recognized as a pleiotrophic cytokine, it is unclear whether its mechanism of action is similar for all cell types. IL-18 has also been shown to promote the production of other cytokines (granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, IL-b and IL-18 [8, 9] ), chemokines (monocyte chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1a [9] ), and to inhibit the production of IL-10 [8] . However, recent reports failed to demonstrate this inhibition [9, 10] . As such, it seems that IL-18 may play a prominent role in the regulation of immune responses in an autocrine, paracrine and even chemotactic manner.
Studies on liver [1, 11] , pancreatic tissue [12] and skin [13] have localized IL-18 mainly to activated macrophages and keratinocytes. In addition, TAKEUCHI et al. [14] have demonstrated high expression of IL-18 in intestinal mucosal epithelial cells. To date, however, no studies have investigated the cellular expression of IL-18 within the airways. In this study, in situ hybridization and immunocytochemistry were used to examine IL-18 expression within lung tissue from Balb/c mice following challenge with agents that induce Th1 and Th2 cytokine production (LPS [15] and ovalbumin (OVA) [16] , respectively). As a clinical correlate, bronchial biopsies from patients with the Th1 and Th2 mediated diseases, sarcoidosis and asthma, respectively were also examined. Immunocytochemistry was employed to determine the expression of IFN-c, IL-5 and the presence of eosinophils.
Materials and methods

Animals
Male Balb/c mice (6±8 weeks old) were obtained from a commercial supplier (Jackson Laboratories, Bar Harbor, ME, USA) and housed in a conventional animal facility at the authors' laboratory. Six animals were challenged with LPS (Sigma Chemical Co., St. Louis, MO, USA) and six sensitized and studied 14 days later following acute challenge with OVA (Sigma Chemical Co.). Normal nonchallenged mice were used as controls. All methods used in these experiments were evaluated and approved by the Animal Ethics committee at McGill University.
Study design
Lipopolysaccharide challenge. Six Balb/c mice were challenged with 10 mg of LPS by intraperitoneal injection, as previously described [17] . LPS administration has been shown to induce the expression of the Th1 cytokines IL-12 and IFN-c [15] and other pro-inflammatory changes within the lung [17] .
Antigen sensitization and challenge. Six Balb/c mice were sensitized and challenged with OVA according to a protocol modified from that previously shown to induce late airway responses and airway inflammation in rats [18] . Briefly, 100 mg OVA and 0.43 mg aluminium hydroxide gel (BHD Chemicals, Poole, UK) were dissolved in 0.5 mL of saline and injected subcutaneously, while 0.5 mL Bordetella Pertussis vaccine (IAF BioVac, Laval, Quebec, Canada) with 2610 9 heat-killed organisms was injected intraperitoneally as an adjuvant. Fourteen days after sensitization, intratracheal challenge with OVA was performed. The mice were sedated with xylazine (8 mg . kg -1 i.p.), anaesthetized with sodium pentobarbital (70 mg . kg -1 i.p.) and then restrained on a board at a fixed angle. Mice then received OVA (100 mg; 50 mL) by intratracheal instillation using a bluntended 21G needle. The mice were then allowed to recover from the anaesthesia.
Lung dissection and processing. Six hours following OVA and 24 h following LPS challenge, time points associated with optimal changes in cytokine expression [16, 17] , the lungs were obtained. Both LPS-and OVA-treated mice were anaesthetized with a lethal dose of sodium pentobarbital (60 mg . kg -1 ). The animals were intubated by tracheotomy with a blunt-ended 21G syringe, the lungs filled with 1 mL of 4% paraformaldehyde, so as to be fixed in an inflated state. The anterior chest wall was removed and mice were exsanguinated by vena cava section. The heart and lungs were excised together, to ensure that the lungs were not damaged in the process, and then placed in 4% paraformaldehyde for a period of 2 h and then washed in 15% sucrose/phosphate buffered saline (PBS) three times (1 h each). Following this, tissue was blocked in optimal cutting temperature (OCT) medium (Miles Inc., Elkhart, IN, USA) and snap frozen in liquid nitrogen-cooled isopentane. Blocks were stored at -808C until required.
Subjects
Six patients with active sarcoidosis, six asthmatics and six normal control subjects were entered into the study. Ethical approval for the study was obtained from the Calmette Hospital Ethics Committee and the Montreal Chest Institute, respectively. Written informed consent was obtained from all patients and subjects before the bronchoscopy.
Sarcoidosis. The sarcoidosis patients (five females and one male), with a mean age of 47 yrs (range 31±65), were newly diagnosed with active disease. All patients were nonsmokers, had no history of allergy, exhibited a negative skin prick test to common aeroallergens and had not received any corticosteroid treatment in the last year. Pulmonary sarcoidosis was diagnosed on the basis of previously described criteria [19] which included lung or mediastinal lymph node biopsy demonstrating evidence of noncaseating epithelioid cell granulomas. All patients had a confirmed histological diagnosis of sarcoidosis and radiographical staging indicated that four patients had stage II and two patients had stage I disease. Active sarcoidosis was assessed by a number of criteria: 1) the recent development or increase of cough or dyspnoea; and/or 2) systemic symptoms such as cutaneous lesions, weakness, fever, arthralgia; and/or 3) increasing opacities on chest radiograph. Patients did not exhibit any airflow limitation as measured by per cent predicted forced expiratory volume in one second (FEV1), with a mean of 101.7% pred (range 77±122) or pulmonary restriction. The patients were recruited through the Department of Pneumoimmunoallergy, Calmette Hospital, Lille, France.
Asthmatics. Asthma was diagnosed according to the American Thoracic Society criteria [20] . All patients (three females, three males), with a mean age of 38 yrs (range 19±60), were nonsmokers and had not received inhaled or oral steroid therapy in the 3 months prior to recruitment. Asthmatic subjects (three atopic, three nonatopic) were studied in a stable condition and had clinically mild asthma with a baseline FEV1 >70% pred (range 74 ±128). All asthmatic subjects had an increased bronchial reactivity to inhaled methacholine as measured by the provocative dose of methacholine causing a 20% fall in FEV1 (PC20) of <8 mg . mL -1 .
Control subjects. Control subjects (two females, four males), with mean age of 34 yrs (range 23±54), recruited for this study had no history of asthma or allergy, were nonsmokers and were free of any other pulmonary disease. PC20 values for these patients were all >16 mg . mL
Bronchoscopy. Bronchial biopsies were obtained from the patients with sarcoidosis and asthma, and normal control subjects by fibreoptic bronchoscopy performed following the American Thoracic Society guidelines [21] . Patients were given an intravenous injection of midazolam (1±5 mg) and a metered dose inhalation of albuterol (400 mg). A 4% lidocaine solution was used for topical anaesthesia, continuous oxymetry was performed and oxygen was given throughout the procedure. Six to eight biopsies were obtained from the segmental divisions at the right lower and middle lobe using alligator forceps (Olympus Corp., Tokyo, Japan). Bronchial biopsies were blocked immediately by embedding the tissue in OCT medium and snap freezing it in liquid nitrogen-cooled isopentane. Blocks were stored at -808C until use.
Immunocytochemistry. Cryostat sections were prepared from blocks of both human and murine lung tissue. Cytokine expression was assessed using the alkaline phosphatase anti-alkaline phosphatase (APAAP) staining method [22] with biotinylated goat anti-mouse IFN-c (DAKO Canada Inc., Missisauga, Ontario, Canada) and rat anti-mouse monoclonal IL-5 antibodies (TRFK-5; Schering-Plough Research Institute, NJ, USA). The presence of eosinophils was determined using a rabbit anti-mouse antibody against major basic protein (MBP; a kind gift from G. Gleich, Mayo Clinic, Rochester, MN, USA). The reaction was visualized using fast red TR (Sigma Chemical Co.). Mouse anti-human monoclonal antibody was employed to detect IL-18 immunoreactivity in human lung sections (R&D Systems Inc., Minneapolis, MN, USA) with the avidin-biotin complex (ABC) method and diaminobenzidine for visualization [23] . All sections were counterstained with haematoxylin. Negative control experiments were performed in a similar manner but in the absence of the primary antibody.
In situ hybridization. In situ hybridization was employed to examine the expression of mouse IL-18 messenger ribonucleic acid (mRNA) as seen previously [24] . Probes complementary to IL-18 mRNA were prepared from complementary deoxyribonucleic acid (cDNA) cloned in a pMuGF37B-5 vector (Stratagene La Jolla, CA, USA) and linearized with the restriction enzymes Kpn-1 for anti-sense (complementary) and Sac-1 for sense (identical) probes. In the presence of 35 S-uridine triphosphate (UTP), the RNA probes were generated by in vitro transcription using the polymerase enzymes T7 and T3. Cryostat sections of lung tissue were permeabilized with 0.1 mg . mL -1 proteinase K and then prehybridized with 50% formamide and 26 standard saline citrate. Following application of the radiolabelled probe (0.75610 6 cpm . section), the sections were hybridized at 428C overnight. High stringency post-hybridization washes, using decreasing concentrations of standard saline nitrate (SSC) solution (46-0.16 SSC) at a relatively high temperature of 428C, were used to reduce nonspecific binding and excess probe was destroyed by treating the slides with an Rnase A solution (20 mg . mL -1 ). The hybridization signal was visualized by incubating the sections overnight with Amersham LM-2 emulsion (Amersham, Oakville, Ontario, Canada), storing them at 48C for a period of 12±14 days, development in Kodak D-19 solution (Eastmean kodak, Torronto, Canada) and counterstaining with haematoxylin. Slides were examined using light microscopy and a positive signal was identified as a collection of dense silver grains overlying the cells. Negative control experiments using sense probes and RNase pretreatment of sections prior to antisense probe application were performed to confirm probe specificity.
Quantification and statistical analysis. Slides were coded and read blindly using an Olympus light microscope (Carson Group Inc., Markam, Ontario, Canada) at 2006 magnification. The graticule was placed under the basement membrane, the number of positive cells were counted and reported as the mean of at least 6±8 grids and expressed as number of positive cells per square millimetre of membrane. Epithelial staining was quantified as a per cent positive staining of the total epithelium. Data were expressed as meanSD and analysed using either the Kolmogorov-Smirnov two sample test or analysis of variance (ANOVA) (SyStat version 7.0; SyStat Inc. Evanston, IL, USA); p<0.05 was considered significant.
Results
Murine expression of interleukin-18 messenger ribonucleic acid
Specific IL-18 mRNA signals were detected in all animals. While the majority of the signal was localized to airway epithelium, mainly cuboidal in phenotype, the inflammatory cells within the airway wall and parenchyma also expressed IL-18 mRNA ( fig. 1) . Histologically, these cells were mostly mononuclear, exhibiting features consistent with the lymphocyte. A number of granulocytes, mainly neutrophils, were also positive for IL-18 mRNA, particularly in the LPS-treated group. Figure 2 shows that the percentage of epithelial cells positive for IL-18 mRNA per square millimetre of basement membrane was significantly higher in the LPS treated animals (579.1; fig. 1a ) compared to the control mice (15.53.73; p< 0.001) as well as OVA-challenged mice (6.34.0; p< 0.001; fig. 1b ). Furthermore, there were significantly fewer IL-18 mRNA positive cells in OVA challenged animals compared to the control (p<0.05). The number of submucosal inflammatory cells expressing IL-18 mRNA per square millimetre of membrane is illustrated in figure  3 . Similarly, more IL-18 mRNA positive cells were seen within the lungs of the LPS-treated mice (50.59.1) compared to the control (18.34.7; p<0.001) and OVAchallenged mice (8.03.9; p<0.001). No specific mRNA was detected in the alveolar epithelium or airway smooth muscle.
Interferon gamma, interleukin-5 and major basic protein immunoreactivity within the murine lung Figure 4 shows the mean number of IFN-c, IL-5 and MBP-immunoreactive cells in lung sections from LPStreated, OVA-challenged and control mice. Animals treated with LPS exhibited a higher number of IFN-c immunoreactive cells (30.174.31) compared to the control group (9.52.9; p<0.001, fig. 4a ). An increase in MBP (6.52.4) and IL-5 (6.01.7) immunoreactivity was also detected in LPS-treated animals, compared to control mice (0.831.3 versus 1.832.1; p<0.05, figs. 4b and c).
Ova-challenged mice were observed to have a large number (mainly around the airways) of cells expressing MBP (39.010.3) and IL-5 (29.37.0) immunoreactivity, significantly higher than the LPS-treated or control group (p<0.001, figs. 4a and b). Scattered IFN-c-positive cells were also detected following OVA challenge, however, their number was substantially lower than LPS-treated and control mice (data not shown).
Interleukin-18 immunoreactivity within the human airway epithelium Figure 5 illustrates the percentage of epithelium exhibiting IL-18 immunoreactivity within bronchial biopsies from control subjects and patients with either sarcoidosis or asthma. Bronchial tissue from all three groups exhibited positive staining for IL-18, mainly within columnar epithelial cells. The percentage of epithelium demonstrating IL-18 immunoreactivity was significantly higher in patients with sarcoidosis (75.013.8; p<0.001) and significantly less within asthmatic tissue (5.85.8; p<0.001), compared to normal control subjects (34.2 11.6).
Discussion
This study set out to examine the pulmonary expression of IL-18 under conditions characterized by Th1 and Th2 cytokine expression. The results demonstrate a constitutive expression of IL-18 within lung tissue from control mice and bronchial biopsies from normal human subjects. An increase in the number of IL-18 positive cells was observed within LPS-treated mice and sarcoidosis patients when compared to control groups, while OVA-challenged mice and asthmatic patients exhibited fewer IL-18 positive cells. These data also show that LPS-treated animals exhibited higher IFN-c immunoreactivity, while the number of IL-5 and MBP immunoreactive cells was increased both within animals that underwent OVA challenge as well as those which received LPS treatment.
To date, IL-18 has been identified mainly within activated macrophages, keratinocytes and within intestinal epithelial cells [1, 11±14] . Although IL-18 mRNA has been demonstrated in mouse lung homogenates following infection with Cryptococcus neoformans [25] , the cellular expression of this cytokine within the lung has not yet been characterized. This study has shown that IL-18 is present within the airway wall and parenchyma and that the majority, both in murine and human tissue, was seen within the epithelium. Many studies have now demonstrated the importance of the epithelium in immune defence, not merely as a protective barrier but also as an active cytokine and chemokine producer [26±28] . The results of this study identify IL-18 as a new member of this group of epithelial-derived mediators. While the significance of IL-18 expression by airway epithelium is not yet clear, it is possible that it acts on intraepithelial Tcells, many of which express the cd T-cell receptor (TCR) and are potent producers of IFN-c [29] . Alternatively, IL-18 has been shown to induce IFN-c expression from bone marrow derived macrophages [3] , which would suggest that it may also act on alveolar macrophages. The epithelium is the first point of contact between the respiratory tract and any inspired foreign agent. The fact that IL-18 is produced by this compartment suggests its role in the early stage of immune responses.
The constitutive pulmonary expression of IL-18 in control lung tissue is consistent with previous work demonstrating low levels of IL-18 mRNA in untreated epidermal cells [13] and may be explained by a recent report describing the regulation of the IL-18 gene by both a constitutively active as well as an inducible promoter [30] . Lung tissue examined 24 h following LPS challenge [17] exhibited a higher number of IFN-c immunoreactive and IL-18 mRNA positive cells within the airway wall and epithelium Correlational analysis indicated only a moderate association between these two, which failed to reach statistical significance. This could be explained by the small sample size (n=6) or alternatively, a tighter relationship may exist between the protein for IL-18 and IFN-c. One of the main functions of IL-18 is its ability to induce the production of IFN-c [2±7]. The elevated number of IL-18-positive cells within bronchial biopsies from sarcoidosis patients is consistent with previous work demonstrating increased expression of IFN-c within the same patient group [30] ; however, it does not rule out the fact that IL-12 may also be involved. While the present study did not examine the expression of IL-4, significantly fewer IL-4 positive cells in bronchoalveolar lavage (BAL) fluid from patients with active sarcoidosis compared to control subjects has been demonstrated [31] . A negative correlation between IL-18 and IL-4 would be suggestive of a reciprocal inhibitory effect between these two cytokines, which may have previously been attributed to IFN-c and IL-12. Further study is required, however, in order to understand how IL-18 fits into the cytokine network.
As anticipated, OVA-challenged mice exhibited significantly more IL-5 and MBP immunoreactive inflammatory cells compared to the control group 6 h following challenge. The increase in these mediators is characteristic of the allergic response to antigen, and in agreement with these results, other studies have also demonstrated similar increases in lung eosinophilia, as early as 3 h, after antigen challenge [32] . Alternatively, the early presence of eosinophils may be due to local maturation of precursor eosinophils within the tissue, a phenomenon currently under study.
More MBP immunoreactivity was observed within LPS-challenged compared to control mice. This finding was unexpected, however, as previous work has demonstrated that LPS administration is associated with eosinophil infiltration [29] . LPS activation of macrophages has been shown to result in the expression of eosinophil chemoattractants [33, 34] and depletion of these cells has been associated with inhibition of tissue eosinophilia [31] . Furthermore, IL-18 has been shown to induce the expression of GM-CSF, an important eosinophil-related cytokine, from these cells [8] . As such, it seems likely that macrophage activation, through LPS stimulation, may be at least partially responsibly for the observed eosinophil influx.
These results demonstrate that interleukin-18 is constitutively expressed in the airway epithelium and parenchyma of murine lung tissue and human bronchial biopsies and that its expression is increased under conditions characterized by T-helper1 cytokine expression such as lipopolysaccharide stimulation and pulmonary sarcoidosis. The results also suggest that the expression of interleukin-18 is reduced within the lungs of mice and humans during T-helper2 cytokine-mediated conditions such as ovalbumin challenge and asthma. While ROBINSON et al. [5] have shown that interleukin-18, unlike interleukin-12, does not directly drive the development of the T-helper1 cytokine profile, epithelial expression of this cytokine indicates its importance during the early stages of host defence and amplification of T-helper1 cytokine expression.
